论文部分内容阅读
目的:探讨胰管支架置入联合生长抑素能否产生预防内镜逆行胰胆管造影（ERCP）术后急性胰腺炎（AP）及高淀粉酶血症（HP）的协同作用。方法:回顾性分析2019年1至12月同济大学附属东方医院胆石病中心实施ERCP的符合纳入标准的325例患者临床资料，按照预防AP方法的不同，分为观察组（胰管支架+生长抑素）和对照组（胰管支架），比较两组患者术后AP、HP的发生率。结果:观察组137例，男62例，女75例，发生AP 5例（3.65%）、HP 10例（7.30%）。对照组188例，男81例，女107例，发生AP 7例（3.72%）、HP 19例（10.11%）。观察组术后AP及HP的发生率均低于对照组，但差异均无统计学意义（χ2=0.001，n P=0.972；χ2=0.768，n P=0.381）。n 结论:胰管支架置入联合生长抑素不会产生预防ERCP术后AP及HP的协同作用。“,”Objective:To explore whether the use of pancreatic stent combined with somatostatin can produce the synergistic effect of preventing acute pancreatitis (AP) and hyperamylasemia (HP) after endoscopic retrograde cholangiopancreatography (ERCP).Methods:From January 2019 to December 2019, the clinical data of 325 patients with ERCP were analyzed retrospectively in cholelithic center of Shanghai East Hospital Affiliated to Tongji University. According to the different methods of AP prevention, the patients were divided into the observation group (pancreatic stent and somatostatin) and the control group (pancreatic stent) and the incidence of AP and HP were compared.Results:In the observation group, there were 5 cases of AP (3.65%) and 10 cases of HP (7.30%). In the control group, there were 7 cases of AP (3.72%) and 19 cases of HP (10.11%). The incidence of AP and HP in the observation group was lower than that in the control group, but the differences were not statistically significant (χ2=0.001, n P=0.972; χ2=0.768, n P=0.381).n Conclusion:The use of pancreatic stent combined with somatostatin will not produce the synergistic effect of preventing AP and HP after ERCP.